Nephrogenic systemic fibrosis: Risk factors suggested from Japanese published cases

British Journal of Radiology

Volumn 83, Issue 991, 2010, Pages 590-595

  Tsushima, Yoshito ^a   Kanal, E ^b   Thomsen, H S ^c  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; JAPANESE; KIDNEY BIOPSY; KIDNEY FAILURE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEDLINE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEER REVIEW; PERITONEAL DIALYSIS; RISK FACTOR; SINGLE DRUG DOSE; SKIN DEFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PERITONEAL DIALYSIS; RISK FACTORS;

EID: 77954510378     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/17689538     Document Type: Article

References (45)

1. Shellock FG, Spinazzi A. MRI safety update 2008: part I. MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol 2008;191:1-11.
2. Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008;180:830-5.
3. Sadowiski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-57.
4. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586-92.
5. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168-75.
6. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-8. (Pubitemid 350202540)
7. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
8. Kanal E, Broome D, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008;246:11-14.
9. Cowper SE. Nephrogenic systemic fibrosis. J Am Coll Radiol 2008;5:23-8.
10. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
11. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62.
12. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66:230-4.
13. Danish Medical Agency. Investigation of the safety of MRI contrast medium Omniscan H. [cited 2009 June 10]. Available from: http://www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID58931/.
14. US Food and Drug Administration. Healthcare professional sheet: gadolinium-containing contrast agents for magnetic resonance imaging (MRI) (marketed as Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance). [cited 2009 June 10]. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142911.htm/.
15. Daiichi Pharmaceutical Co. Omniscan and nephrogenic systemic fibrosis. Mar 2007 (leaflet).
16. Chao CC, Yang CC, Hsiao CH, Pan MK, Lin CH, Hsieh ST. Nephrogenic systemic fibrosis associated with gadolinium use. J Formos Med Assoc 2008;107:270-4.
17. Lu CF, Hsiao CH, Tjiu JW. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor. J Eur Acad Dermatol Venereol 2008;23:339-40.
18. Lim YL, Lee HY, Low SCS, Chan LP, Goh NSG, Pang SM. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007;32:353-8.
19. Chan KH, Tang WY, Hau KC, Lam WY, Lam H, Kwan TH, et al. Nephrogenic systemic fibrosis in a Chinese renal-transplant recipient. Clin Exp Dermatol 2009;34:244-6.
20. Kimura T, Ichihara A, Takimoto C, Takase O, Itaya Y, Konishi K, et al. Nephrogenic systemic dermopathy in a patient with end-stage renal failure. Nippon Touseki Igakukai Zasshi 2004;37:1519-25. (In Japanese with English abstract.)
21. Tanno A, Kawakami M, Kawaguchi Y, Yamamoto I, Yanaginuma M, Okada H, et al. Histopathological analysis of nephrogenic systemic fibrosis. Nippon Jinzou Gakkaishi 2004;46:633. (Meeting abstract in Japanese.)
22. Yamada R, Iwabuchi K, Sasaki M, Takahashi H, Kiyokawa T, Suzuki M, et al. Two cases of nephrogenic fibrosing dermopathy. Nippon Byouri Gakkai Zasshi 2005;94:302. (Meeting abstract in Japanese.)
23. Inoue T, Nagatoya K, Mori T, Kagiya M, Makino S. A case of nephrogenic systemic fibrosis associated with renal sclerosis. Nippon Jinzou Gakkaishi 2005;47:625. (Meeting abstract in Japanese.)
24. Yorimitsu D, Sasaki T, Ueda K, Jyousyo K, Nishi Y, Fujimoto S, et al. A case of nephrogenic fibrosing dermopathy. Nippon Touseki Igakukai Zasshi 2008;41:694. (Meeting abstract in Japanese.)
25. Nakasu I, Asano Y, Idezuki T, Harada S, Kaji K, Igarashi A. A case of nephrogenic fibrosing dermopathy. Nippon Hifika Gakkai Zasshi 2005;115:540. (Meeting abstract in Japanese.)
26. Tsushima Y, Endo K, Okabe K, Sano T. [A case of nephrogenic systemic fibrosis associated with gadodiamide use.] Nippon Touseki Igakukai Zasshi 2007;40:805-10.
27. Soutome A, Hamazaki Y, Hatamochi J, Yamazaki S, Oota C, Matsuoka H. A case of nephrogenic systemic fibrosis (NSF). The 72nd Annual Meeting of the Eastern Japan Division of JDA. 2009:75. (Meeting abstract in Japanese.)
28. Imai C, Kurihara K, Ito M, Orito H, Idezuki T, Igarashi A, et al. [A case of nephrogenic fibrosing dermopathy.] Hifu Rinsyo 2008;50:1235-8.
29. Nakai K, Takeda K, Kimura H, Miura S, Maeda A. Nephrogenic systemic fibrosis in a patient on long-term hemodialysis. Clin Nephrol 2009;71:217-20.
30. Kuwabara N, Sakai T, Tamura H, Ishikura K, Hamasaki Y, Hataya H, et al. A case of nephrogenic systemic fibrosis, suspected due to gadolinium contrast material (Omniscan). Nippon Shouni Jinzoubyou Gakkai Zassi 2007;20:165. (Meeting abstract in Japanese.)
31. Imai T, Ikegami N, Shibuya M, Shirokami K, Fujii H. A case of nephrogenic systemic fibrosis after administration of gadolinium contrast material. In: 38th Nippon Jinzo Gakkai Seibu Gakujyutsutaikai; 2008 September 27.
32. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-7.
33. Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, et al. Nephrogenic systemic fibrosis: center case review. J Mag Reson Imag 2007;26:1198-203.
34. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-4.
35. Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008;190:736-41.
36. The Japanese Society for Dialysis Therapy. Current status of dialysis in Japan. 2007 [cited 2009 June 10]. Available from: http://docs.jsdt.or.jp/ overview/index.html/.
37. Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-16.
38. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007;56:137-41.
39. European Society of Urogenital Radiology. ESUR guidelines on contrast media. Version 7.0.
40. Reilly RF. Risk of nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Nephrol 2008;3:747-51.
41. Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 2008;66:180-3.
42. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis of continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502. (Pubitemid 28303906)
43. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from tow cases and review of the recent literature. Am J Transplant 2007;7:2425-32.
44. Deng A, Bilu Martin D, Spillane A, Chwalek J, Surin-Lord S, Brooks S, et al. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 2010;27:204-10.
45. Barrs TJ. Establishing safeguards for the use of imaging-related drugs. Am J Health-Syst Pharm 2002;59:1449-53.